The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: ReoPro(R)) coated stent in patients with coronary artery disease.
- Author:
Weon KIM
1
;
Myung Ho JEONG
;
Young Joon HONG
;
Seng Hyun LEE
;
Woo Seok PARK
;
Ju Han KIM
;
In Soo KIM
;
Myung Ja CHOI
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Dong Lyun CHO
;
Hoon KIM
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Chonnam National University Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Platelets;
Receptor;
Coronary artery disease;
Restenosis;
Stents
- MeSH:
Blood Platelets*;
Constriction, Pathologic;
Coronary Artery Disease*;
Coronary Restenosis;
Coronary Vessels*;
Death;
Follow-Up Studies;
Glycoproteins*;
Humans;
Length of Stay;
Muscle, Smooth, Vascular;
Myocardial Infarction;
Phenobarbital;
Platelet Aggregation;
Prospective Studies;
Stents*
- From:Korean Journal of Medicine
2003;65(6):652-664
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Previously we reported the inhibition of coronary restenosis with Abciximab (ReoPro(R))-coated stent in a porcine model. ReoPro(R) inhibits platelet aggregation, the proliferation of vascular smooth muscle cells and inflammatory reaction. METHODS: We performed a prospective randomized trial to compare two types of stents for the revascularization in native coronary artery. The primary effective end points were major adverse coronary events (MACE): cardiac death, acute myocardial infarction, target vessel revascularization (TVR), restenosis at 6-month clinical and angiographic follow-up. RESULTS: One hundred fifty-five patients were enrolled between Aug, 2001 and Jun, 2003. Mean ages (56.0 +/- 10.0 vs. 56.9 +/- 10.8 years), baseline diameter stenosis and minimal luminal diameter were not different between the two groups. There was one myocardial infarction and revascularization during hospital stay in control stent group. During clinical follow-up, there were two myocardial infarctions in control group. Follow-up coronary angiogram was done 62.3% (48/77) in coated and 65.4% (51/78) in control groups. Diameter stenosis and late loss were significantly less in the ReoPro(R)-coated stent group compared with controls (16.4 +/- 5.8% vs. 34.3 +/- 6.1%, p=0.009; and 0.33 +/- 0.28 mm vs. 0.88 +/- 0.41 mm; p=0.002). The restenosis and TVR rates of ReoPro-coated stent were relatively lower compared with control stent [14.6% (7/48) vs. 29.4% (15/51), p=0.062; and 9.2% (7/76) vs. 14.7% (11/75); p=0.327]. CONCLUSION: A ReoPro(R)-coated stent is safe and may be effective in the prevention of coronary restenosis.
